AI Article Synopsis
- Short-read next-generation sequencing struggles with accurately genotyping T cell receptor (TCR) loci, hindering our understanding of their genetic variations.
- Rodriguez et al. present a new method that combines probe-based hybrid capture and long-read sequencing to improve this process.
- Their approach allows for fully phased TCR locus haplotypes to be resolved from diploid human genomes, enhancing genetic characterization.
Article Abstract
Short-read next-generation sequencing has failed to adequately genotype the T cell receptor (TCR) loci, limiting our ability to characterize the role of germline TCR variation. In this issue of , Rodriguez et al. describe how a probe-based hybrid capture approach coupled with long-read sequencing can resolve fully phased TCR locus haplotypes from diploid human genomes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9903699 | PMC |
| http://dx.doi.org/10.1016/j.xgen.2022.100231 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system.
Front Immunol
January 2025
Molecular Immunology and Gene Therapy, Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.
Generation of high avidity T cell receptors (TCRs) reactive to tumor-associated antigens (TAA) is impaired by tolerance mechanisms, which is an obstacle to effective T cell therapies for cancer treatment. NY-ESO-1, a human cancer-testis antigen, represents an attractive target for such therapies due to its broad expression in different cancer types and the restricted expression in normal tissues. Utilizing transgenic mice with a diverse human TCR repertoire, we isolated effective TCRs against NY-ESO-1 restricted to HLA-A*02:01.
View Article and Find Full Text PDFUnderstanding the Preclinical Efficacy of Antibody-Drug Conjugates.
Int J Mol Sci
November 2024
Experimental Therapeutics Unit, Oncology Department, Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain.
Antibody-drug conjugates (ADCs) represent a therapeutic modality that guides chemotherapies to tumoral cells by using antibodies against tumor-associated antigens (TAAs). The antibody and the chemotherapy or payload are attached by a chemical structure called the linker. The strategy for the development of this type of drug was based on several rational pillars, including the use of a very potent payload and the use of specific antibodies acting only on antigens expressed on tumoral cells.
View Article and Find Full Text PDFCilostazol counteracts mitochondrial dysfunction in hepatic encephalopathy rat model: Insights into the role of cAMP/AMPK/SIRT1/ PINK-1/parkin hub and p-CREB /BDNF/ TrkB neuroprotective trajectory.
Eur J Pharmacol
January 2025
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Modern University for Technology and Information, Cairo, Egypt. Electronic address:
A devasting stage of chronic hepatic dysfunction is strictly correlated with neurological impairment, signifying hepatic encephalopathy (HE). HE is a multifactorial condition; therefore, hyperammonemia, oxidative stress, neuroinflammation, and mitochondrial dysfunction interplay in HE's progressive development. Cilostazol (Cilo) has shown promising neuroprotective and hepatoprotective effectiveness in different neuronal and hepatic disorders; however, its efficiency against HE hasn't yet been explored.
View Article and Find Full Text PDFEGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer.
Front Oncol
November 2024
Department of Tumor Biobank, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China.
Background: Epidermal growth factor receptor (EGFR) is a key protein in cellular signaling that is overexpressed in many human cancers, making it a compelling therapeutic target. On-target severe skin toxicity has limited its clinical application. Dual-targeting therapy represents a novel approach to overcome the challenges of EGFR-targeted therapies.
View Article and Find Full Text PDFBiomimetic Dendritic Cell-Based Nanovaccines for Reprogramming the Immune Microenvironment to Boost Tumor Immunotherapy.
ACS Nano
December 2024
Biotechnology Center, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, China.
Article Synopsis
- Traditional dendritic cell (DC) vaccines face challenges like poor antigen delivery, ineffective lymph node targeting, and risks from living cell transfers.
- The new HybridDC nanovaccine uses engineered DC membranes and anchors multiple components to enhance antigen presentation and boost anti-tumor immunity.
- HybridDC shows improved targeting of lymphoid tissues, effective treatment against glioma models, and enhances the effectiveness of immune checkpoint blockade therapies, suggesting it could revolutionize personalized cancer immunotherapy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!